Real‐world safety and efficacy of biologics in elderly patients with psoriasis: A multicenter observational study

Clinical trials of biologics have frequently excluded elderly patients, resulting in inadequate data on their safety and efficacy. Additionally, evidence of their safety and efficacy remains limited, despite some real‐world studies. To assess the safety and efficacy of biologics in elderly patients...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2024-12, Vol.51 (12), p.1634-1640
Main Authors: Ohata, Chika, Anezaki, Hisataka, Yanase, Tetsuji, Katayama, Eri, Kaneko, Sakae, Saito, Kanami, Yamane, Mariko, Nakamaru, Sei, Tsuruta, Noriko, Okazaki, Fusako, Ito, Kotaro, Kikuchi, Satoko, Koike, Yuta, Miyagi, Takuya, Sugita, Kazunari, Nakahara, Takeshi, Takezaki, Daiki, Saruwatari, Hiroshi, Yoshida, Yuichi, Yonekura, Kentaro, Higashi, Yuko, Sawada, Yu, Chinuki, Yuko, Yamaguchi, Kazuki, Imafuku, Shinichi
Format: Article
Language:English
Subjects:
Adult
Age Factors
Aged
Biological products
Biological Products - adverse effects
Biological Products - therapeutic use
Biopharmaceuticals
Clinical trials
Dermatologic Agents - adverse effects
Dermatologic Agents - therapeutic use
efficiency
elderly patients
Female
Follow-Up Studies
Humans
Incidence
infection
Infectious diseases
Japan - epidemiology
Male
Middle Aged
Neoplasms - drug therapy
Patients
Psoriasis
Psoriasis - drug therapy
Quality of life
Registries - statistics & numerical data
Safety
Severity of Illness Index
Surveys
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical trials of biologics have frequently excluded elderly patients, resulting in inadequate data on their safety and efficacy. Additionally, evidence of their safety and efficacy remains limited, despite some real‐world studies. To assess the safety and efficacy of biologics in elderly patients with psoriasis, we compared these outcomes in younger patients using data from the West Japan Psoriasis Registry (WJPR). The WJPR consists of approximately 30 facilities in Western Japan, including various healthcare settings. This study enrolled 1395 patients who participated in the 2022 follow‐up survey of the WJPR and were either using or had used biologics during the survey. These included 456 patients in the elderly group (≥65 years) and 939 patients in the younger group (
ISSN:0385-2407
1346-8138
1346-8138
DOI:10.1111/1346-8138.17385